February 21, 2018 08:37 AM EST
R&D

Ab­b­Vie rolls up an­oth­er big win for elagolix as the prospec­tive block­buster sweeps end­points in lat­est PhI­II

John Carroll

Editor & Founder

Al­ready on the fast pri­or­i­ty track at the FDA with their ap­pli­ca­tion to start sell­ing elagolix for en­dometrio­sis, Ab­b­Vie $AB­BV said to­day that the drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times